Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Bernard Hulin"'
Autor:
H. James Harwood, Jr., Stephen F. Petras, Dennis J. Hoover, Dayna C. Mankowski, Victor F. Soliman, Eliot D. Sugarman, Bernard Hulin, Younggil Kwon, E. Michael Gibbs, James T. Mayne, Judith L. Treadway
Publikováno v:
Journal of Lipid Research, Vol 46, Iss 3, Pp 547-563 (2005)
Diabetic dyslipidemia requires simultaneous treatment with hypoglycemic agents and lipid-modulating drugs. We recently described glycogen phosphorylase inhibitors that reduce glycogenolysis in cells and lower plasma glucose in ob/ob mice (J. Med. Che
Externí odkaz:
https://doaj.org/article/5ebbe43f58a84c83843fcaee4e9c9fbd
Autor:
Judith L. Treadway, David W. Piotrowski, R. Kirk McPherson, Jana Polivkova, Anne M. Brodeur, Shenping Liu, Bernard Hulin, David D. Boyer, Stephen J. Orena, Xiayang Qiu, Maria A. Vanvolkenburg, Dennis E. Danley, Donald C. Wilder, Janice C. Parker, Shawn D. Doran, Carolyn B. Soglia, Mark Ammirati, Kim M. Andrews
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:1991-1995
A series of 4-substituted proline amides was synthesized and evaluated as inhibitors of dipeptidyl pepdidase IV for the treatment of type 2 diabetes. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methan
Autor:
Shawn Cabral, Michael G. Lopaze, Kim M. Andrews, Bernard Hulin, Janice C. Parker, Maria A. Van Volkenburg
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 15:4770-4773
Cyclohexylglycine amides of various fluorinated pyrrolidines and azetidines were prepared and tested for activity against dipeptidyl peptidase IV and in vivo in the KK mouse model of type 2 diabetes. The tetrafluoropyrrolidide, cis-3,4-difluoropyrrol
Publikováno v:
Tetrahedron Letters. 48:7134-7136
Traditional reductive amination of substituted cyclohexanones are either selective toward the formation of cis-products or show low selectivity. Herein we report a selective procedure for the reductive amination of substituted cyclohexanones with pri
Publikováno v:
Current Pharmaceutical Design. 2:85-102
Abstract: In 1982, Takeda Inc. reported the discovery of ciglitazone (5-[4-(l methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione, ADD-3878), a compound which lowers blood glucose in animal models of Non Insulin Dependent Diabetes without an inc
Publikováno v:
Journal of Medicinal Chemistry. 39:3897-3907
The thiazolidinedione moiety of ciglitazone and its analogues can be replaced by an alpha-alkoxy or alpha-thioether carboxylic acid group. The influence of the nature of the R group, the length of the connector to the aromatic backbone of the molecul
Publikováno v:
Scopus-Elsevier
1,5-Cyclooctadiene can be stereoselectively transformed into a substituted bicyclo[3.3.0]octane ring system under palladium catalysis with concomitant formation of three carbon-carbon bonds. Reaction with an aryl iodide or triflate and malonate gives
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 3:703-706
Biotin conjugates of darglitazone (CP-86,325), a new antihyperglycemic agent, were prepared. The protocol used allows variation of the chain linking the two units and is applicable to other ligands containing a ketone function.
Autor:
Johnson Michael R, P. L. Kelbaugh, Ruth E. McDermott, W. H. Kappeler, P. Merrigan, Gerald F. Holland, David Alan Clark, R W Stevenson, F. J. Rajeckas, Bernard Hulin, James F. Eggler, R. T. Suleske, E. M. Gibbs, Robert A. Volkmann, D. K. Kreutter, N. J. Hutson, D. L. Tickner, C. H. Lamphere, M. N. Krupp, E. G. Andrews, Steven W. Goldstein
Publikováno v:
ChemInform. 22
Autor:
W. H. Kappeler, Ruth E. McDermott, Diana M. Lewis, David Alan Clark, Bernard Hulin, James P. Rizzi, Paul J. Dambek, C. H. Lamphere, Steven W. Goldstein
Publikováno v:
ChemInform. 24
A new series of thiazolidine-2,4-diones was obtained by replacing the ether function of englitazone with various functional groups, i.e., a ketone, alcohol, or olefin moiety. These compounds lower blood glucose levels in the genetically obese and ins